Escalon Medical Corp.00008626686/3010-QTRUE3/31/20232023Q3FALSEtruefalsefalse7,415,329FALSE000-201270.0010.00135,000,00035,000,0007,415,3297,415,3297,415,3297,415,3290.0010.0012,000,0002,000,0002,000,0002,000,00000008626682022-07-012023-03-3100008626682023-05-12xbrli:shares00008626682023-03-31iso4217:USD00008626682022-06-300000862668us-gaap:SecuredDebtMember2023-03-310000862668us-gaap:SecuredDebtMember2022-06-30iso4217:USDxbrli:shares0000862668us-gaap:ProductMember2023-01-012023-03-310000862668us-gaap:ProductMember2022-01-012022-03-310000862668us-gaap:ProductMember2022-07-012023-03-310000862668us-gaap:ProductMember2021-07-012022-03-310000862668us-gaap:ServiceMember2023-01-012023-03-310000862668us-gaap:ServiceMember2022-01-012022-03-310000862668us-gaap:ServiceMember2022-07-012023-03-310000862668us-gaap:ServiceMember2021-07-012022-03-3100008626682023-01-012023-03-3100008626682022-01-012022-03-3100008626682021-07-012022-03-310000862668us-gaap:PreferredStockMember2022-06-300000862668us-gaap:CommonStockMember2022-06-300000862668us-gaap:AdditionalPaidInCapitalMember2022-06-300000862668us-gaap:RetainedEarningsMember2022-06-300000862668us-gaap:PreferredStockMember2022-07-012022-09-300000862668us-gaap:CommonStockMember2022-07-012022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000862668us-gaap:RetainedEarningsMember2022-07-012022-09-3000008626682022-07-012022-09-300000862668us-gaap:PreferredStockMember2022-09-300000862668us-gaap:CommonStockMember2022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-09-300000862668us-gaap:RetainedEarningsMember2022-09-3000008626682022-09-300000862668us-gaap:PreferredStockMember2022-10-012022-12-310000862668us-gaap:CommonStockMember2022-10-012022-12-310000862668us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000862668us-gaap:RetainedEarningsMember2022-10-012022-12-3100008626682022-10-012022-12-310000862668us-gaap:PreferredStockMember2022-12-310000862668us-gaap:CommonStockMember2022-12-310000862668us-gaap:AdditionalPaidInCapitalMember2022-12-310000862668us-gaap:RetainedEarningsMember2022-12-3100008626682022-12-310000862668us-gaap:PreferredStockMember2023-01-012023-03-310000862668us-gaap:CommonStockMember2023-01-012023-03-310000862668us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000862668us-gaap:RetainedEarningsMember2023-01-012023-03-310000862668us-gaap:PreferredStockMember2023-03-310000862668us-gaap:CommonStockMember2023-03-310000862668us-gaap:AdditionalPaidInCapitalMember2023-03-310000862668us-gaap:RetainedEarningsMember2023-03-310000862668us-gaap:PreferredStockMember2021-06-300000862668us-gaap:CommonStockMember2021-06-300000862668us-gaap:AdditionalPaidInCapitalMember2021-06-300000862668us-gaap:RetainedEarningsMember2021-06-3000008626682021-06-300000862668us-gaap:PreferredStockMember2021-07-012021-09-300000862668us-gaap:CommonStockMember2021-07-012021-09-300000862668us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000862668us-gaap:RetainedEarningsMember2021-07-012021-09-3000008626682021-07-012021-09-300000862668us-gaap:PreferredStockMember2021-09-300000862668us-gaap:CommonStockMember2021-09-300000862668us-gaap:AdditionalPaidInCapitalMember2021-09-300000862668us-gaap:RetainedEarningsMember2021-09-3000008626682021-09-300000862668us-gaap:PreferredStockMember2021-10-012021-12-310000862668us-gaap:CommonStockMember2021-10-012021-12-310000862668us-gaap:AdditionalPaidInCapitalMember2021-10-012021-12-310000862668us-gaap:RetainedEarningsMember2021-10-012021-12-3100008626682021-10-012021-12-310000862668us-gaap:PreferredStockMember2021-12-310000862668us-gaap:CommonStockMember2021-12-310000862668us-gaap:AdditionalPaidInCapitalMember2021-12-310000862668us-gaap:RetainedEarningsMember2021-12-3100008626682021-12-310000862668us-gaap:PreferredStockMember2022-01-012022-03-310000862668us-gaap:CommonStockMember2022-01-012022-03-310000862668us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000862668us-gaap:RetainedEarningsMember2022-01-012022-03-310000862668us-gaap:PreferredStockMember2022-03-310000862668us-gaap:CommonStockMember2022-03-310000862668us-gaap:AdditionalPaidInCapitalMember2022-03-310000862668us-gaap:RetainedEarningsMember2022-03-3100008626682022-03-310000862668us-gaap:ConvertiblePreferredStockMember2023-01-012023-03-310000862668us-gaap:ConvertiblePreferredStockMember2022-01-012022-03-310000862668us-gaap:ConvertiblePreferredStockMember2022-07-012023-03-310000862668us-gaap:ConvertiblePreferredStockMember2021-07-012022-03-310000862668us-gaap:StockOptionMember2023-01-012023-03-310000862668us-gaap:StockOptionMember2022-01-012022-03-310000862668us-gaap:StockOptionMember2022-07-012023-03-310000862668us-gaap:StockOptionMember2021-07-012022-03-3100008626682018-02-14esmc:votexbrli:pure00008626682021-07-012022-06-300000862668us-gaap:NotesPayableToBanksMember2018-06-290000862668us-gaap:NotesPayableToBanksMember2022-07-012023-03-310000862668us-gaap:NotesPayableToBanksMemberesmc:TDBankMember2023-03-290000862668us-gaap:NotesPayableToBanksMemberesmc:TDBankMember2023-03-292023-03-290000862668us-gaap:SubsequentEventMemberus-gaap:NotesPayableToBanksMemberesmc:TDBankMember2023-04-292023-04-290000862668us-gaap:NotesPayableToBanksMemberesmc:TDBankMember2023-03-310000862668esmc:PayrollProtectionProgramLoanMember2022-09-300000862668us-gaap:SecuredDebtMember2023-03-310000862668us-gaap:SecuredDebtMember2023-03-312023-03-310000862668us-gaap:SecuredDebtMember2022-07-012023-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:SalesRevenueNetMemberesmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMemberesmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberesmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2021-07-012022-03-310000862668esmc:AccountsReceivableBenchmarkMember2022-07-012023-03-310000862668esmc:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:AccountsReceivableMember2022-07-012022-09-300000862668esmc:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000862668us-gaap:AccountsReceivableMember2022-07-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2023-01-012023-03-310000862668esmc:SupplierTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMember2023-01-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2022-07-012023-03-310000862668esmc:SupplierTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:AccountsReceivableMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2022-01-012022-03-310000862668esmc:SupplierTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:AccountsReceivableMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2021-07-012022-03-310000862668esmc:SupplierTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:SupplierConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:AccountsPayableBenchmarkMember2022-07-012023-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberesmc:AccountsPayableBenchmarkMember2022-07-012023-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:AccountsPayableBenchmarkMember2022-07-012022-09-300000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberesmc:AccountsPayableBenchmarkMember2022-07-012022-12-310000862668us-gaap:SalesRevenueNetMembercountry:USus-gaap:GeographicConcentrationRiskMember2023-01-012023-03-310000862668us-gaap:SalesRevenueNetMembercountry:USus-gaap:GeographicConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMembercountry:USus-gaap:GeographicConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:SalesRevenueNetMembercountry:USus-gaap:GeographicConcentrationRiskMember2021-07-012022-03-310000862668country:USus-gaap:GeographicConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-07-012023-03-310000862668us-gaap:GeographicConcentrationRiskMember2021-07-012022-03-310000862668us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-07-012022-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 FORM 10-Q
QUARTERLY PERIOD PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934


For the Quarterly Period ended March 31, 2023
Commission File Number 0-20127


Escalon Medical Corp.
(Exact name of registrant as specified in its charter)

Pennsylvania 33-0272839
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
435 Devon Park Drive, Suite 824, Wayne, PA 19087
(Address of principal executive offices, including zip code)
(610) 688-6830
(Registrant’s telephone number, including area code)


N/A
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act: NONE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company. or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 


Large accelerated fileroAccelerated filero
Non-accelerated filer
x
Smaller reporting companyx
Emerging growth companyo

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  o    No  x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,415,329 shares of common stock, $0.001 par value, outstanding as of May 12, 2023.




TABLE OF CONTENTS
  Page
PART I Financial Information
Item I.
Item 2.
Item 3.
Item 4.
PART II Other Information
Item 6.



1

PART I. FINANCIAL INFORMATION


Item I. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
March 31,
2023		June 30,
2022
ASSETS
Current assets:
Cash and cash equivalents$544,320 $593,869 
Restricted cash256,240 256,165 
Accounts receivable, net1,742,723 1,541,750 
Inventories, net1,665,193 1,603,955 
Other current assets162,247 190,043 
Total current assets4,370,723 4,185,782 
Property and equipment, net39,928 52,660 
Right-of-use assets572,485 788,257 
License and patent, net74,898 82,750 
Other long term assets62,788 62,788 
Total assets$5,120,822 $5,172,237 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Line of credit $— $201,575 
Current portion of note payable 36,663 3,401 
Current portion of EIDL loan3,055 3,105 
Accounts payable1,047,826 1,012,451 
Accrued expenses868,933 901,996 
Related party accrued interest 112,389 112,389 
Current portion of operating lease liabilities
324,060 304,737 
Deferred revenue295,398 332,383 
Other short-term liabilities87,006 129,961 
Total current liabilities2,775,330 3,001,998 
Note payable, net of current portion169,036 3,888 
EIDL loan, net of current portion 146,904 149,540 
Operating lease liabilities, net of current portion293,067 538,794 
Total long-term liabilities609,007 692,222 
Total liabilities3,384,337 3,694,220 
Shareholders' equity:
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $909,466 and $870,731)645,000 645,000 
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415 
Additional paid-in capital69,702,043 69,702,043 
Accumulated deficit(68,617,973)(68,876,441)
Total shareholders’ equity1,736,485 1,478,017 
Total liabilities and shareholders’ equity$5,120,822 $5,172,237 
See notes to unaudited condensed consolidated financial statements
2


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2023202220232022
Net revenues:
Products$3,285,396 $2,259,860 $8,582,183 $7,261,134 
Service plans148,918 156,267 462,436 530,819 
Revenues, net3,434,314 2,416,127 9,044,619 7,791,953 
Costs and expenses:
Cost of goods sold1,720,853 1,477,651 5,021,470 4,681,088 
Marketing, general and administrative938,161 1,001,074 3,108,177 2,855,373 
Research and development185,750 229,315 641,316 780,943 
Total costs and expenses
2,844,764 2,708,040 8,770,963 8,317,404 
Income (loss) from operations589,550 (291,913)273,656 (525,451)
Other (expense) income
Other income— — — 506,305 
Interest expense(4,315)(4,103)(15,188)(12,804)
Total other (expense) income, net(4,315)(4,103)(15,188)493,501 
Net income (loss) 585,235 (296,016)258,468 (31,950)
Undeclared dividends on preferred stocks13,006 13,006 38,735 39,018 
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Net earnings (loss) per share
Basic earnings (loss) per share$0.08 $(0.04)$0.03 $(0.01)
Diluted earnings (loss) per share$0.04 $(0.04)$0.02 $(0.01)
Weighted average shares—basic7,415,329 7,415,3297,415,329 7,415,329
Weighted average shares—diluted13,478,9367,415,32913,478,9367,415,329
See notes to unaudited condensed consolidated financial statements
3


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2023 AND 2022
(UNAUDITED)


 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20222,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,876,441)$1,478,017 
Net loss— — — — — (320,724)(320,724)
Balance at September 30, 20222,000,000 645,000 7,415,329 7,415 69,702,043 (69,197,165)1,157,293 
Net loss— — — — — (6,043)(6,043)
Balance at December 31, 20222,000,000 645,000 7,415,329 7,415 69,702,043 (69,203,208)1,151,250 
Net income— — — — — 585,235 585,235 
Balance at March 31, 20232,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,617,973)$1,736,485 

 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20212,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,894,522)$1,459,936 
Net income— — — — — 317,220 317,220 
Balance at September 30, 20212,000,000 645,000 7,415,329 7,415 69,702,043 (68,577,302)1,777,156 
Net loss— — — — — (53,154)(53,154)
Balance at December 31, 20212,000,000 645,000 7,415,329 7,415 69,702,043 (68,630,456)1,724,002 
Net loss— — — — — (296,016)(296,016)
Balance at March 31, 20222,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,926,472)$1,427,986 


See notes to unaudited condensed consolidated financial statements
4

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
For the Nine Months Ended March 31,
20232022
Cash Flows from Operating Activities:
Net income (loss)$258,468 $(31,950)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Change in allowance of doubtful accounts(93,400)15,000 
Other income
— (506,305)
Depreciation and amortization
34,424 36,941 
Non cash lease expense
215,772 209,277 
Change in operating assets and liabilities:
Accounts receivable(107,573)(62,946)
Inventories(61,238)(128,095)
Other current and non-current assets27,798 (4,269)
Accounts payable 35,375 16,653 
   Accrued expenses
(33,063)183,579 
Change in operating lease liability
(226,404)(217,002)
Deferred revenue(36,985)(61,002)
  Other short term and long term liabilities(42,955)(47,006)
Net cash used in operating activities(29,781)(597,125)
Cash Flows from Investing Activities:
Purchase of equipment
(6,687)— 
 Purchase of patents(7,155)— 
Net cash used in investing activities
(13,842)— 
Cash Flows from Financing Activities:
Repayment of note payable(3,165)(2,936)
Repayment of EIDL loan(2,686)(2,196)
Net cash used in financing activities(5,851)(5,132)
Net decrease in cash, cash equivalents and restricted cash(49,474)(602,257)
Cash, cash equivalents and restricted cash, beginning of period850,034 1,906,890 
Cash, cash equivalents and restricted cash, end of period$800,560 $1,304,633 
Cash, cash equivalents and restricted cash consist of the following:
End of period
Cash and cash equivalents$544,320 $1,048,500 
Restricted cash 256,240 256,133 
5

$800,560 $1,304,633 
Beginning of period
Cash and cash equivalents$593,869 $1,650,970 
Restricted cash 256,165 255,920 
$850,034 $1,906,890 

Supplemental Schedule of Cash Flow Information:
Interest paid$15,697 $12,534 
See notes to unaudited condensed consolidated financial statements
6

Escalon Medical Corp. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization and Basis of Presentation

          Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.

    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.

    The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2022. The results of operations for the three and nine months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year.

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which the Company has business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations. The Company will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on customer demand, suppliers’ ability to deliver products, cybersecurity risks and its liquidity and access to capital.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”

2. Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. As of March 31, 2023, the Company had an accumulated deficit of $68.6 million, and historically incurred recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
7


The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, implementing cost-cutting measures and seeking to sell certain assets. The Company may not be successful in any of these efforts.

3. Summary of Accounting Policies

Recently Issued Accounting Standards
In March 2023, the FASB issued ASU 2023-01, which amends the application of ASU 2016-02, Leases (Topic 842), related to leases with entities under common control, also referred to as common control leases. The amendments to this update require an entity to consider the useful life of leasehold improvements associated with common control leases from the perspective of the common control group and amortize the leasehold improvements over the useful life of the assets to the common control group, instead of the term of the lease. Any remaining value for the leasehold improvement at the end of the lease would be adjusted through equity. The standard is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.

Quarterly Reporting
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2023 and the results of operations and cash flows for the interim periods ended March 31, 2023 and 2022, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on September 28, 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2023.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable

Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $143,000 and $236,000 as of March 31, 2023, and June 30, 2022, respectively. The Company increased allowance for doubtful accounts at the end of fiscal year 2022 for the middle east government contracts when the invoices were outstanding for over a year and reduced the allowance for doubtful accounts when it received the payments during the quarter ended March 31, 2023.

Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less
8

than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.

PPP Loans
    Prior to the forgiveness Company's policy was to account for the PPP loan (See Note 7) as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released, at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021, and was included in other income in the unaudited condensed consolidated income statement for the nine-month period ended March 31, 2022.

Deferred Revenues

    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.

(in thousands)Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Beginning of Period$259 $311 $332 $364 
Additions185 148 425 470
Revenue Recognized149 156 462 531 
End of Period$295 $303 $295 $303 

Earnings (loss) Per Share    
Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of March 31, 2023, and 2022, the average market prices for the three-month and nine-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month and nine-month periods ended March 31, 2022. Therefore, basic and diluted loss per common share for the three-month and nine-month periods ended March 31, 2022 are the same.
9

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Numerator:
  Numerator for basic loss per share:
 Net income (loss)$585,235 $(296,016)$258,468 $(31,950)
Undeclared dividends on preferred stock13,006 13,006 38,735 39,018 
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Numerator for diluted earnings per share:
Net income (loss) applicable to common shareholders$572,229 $(309,022)$219,733 $(70,968)
Undeclared dividends on preferred stock13,006 — 38,735 — 
Diluted income (loss) $585,235 $(309,022)$258,468 $(70,968)
Denominator for basic earnings (loss) per share
Denominator for basic earnings (loss) per share - weighted average shares outstanding
7,415,3297,415,329 7,415,3297,415,329 
Weighted average preferred stock converted to common stock6,063,607 — 6,063,607 — 
 Denominator for diluted earnings (loss) assumed conversion13,478,936 7,415,329 13,478,936 7,415,329 
Net earnings (loss) per share:
Basic net earnings (loss) per share$0.08 $(0.04)$0.03 $(0.01)
Earnings (loss) per share$0.04 $(0.04)$0.02 $(0.01)

The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

10

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock— 5,720,993 — 5,720,993 
Total potential dilutive securities not included in income per share157,000 5,877,993 157,000 5,877,993 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2023, and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of March 31, 2023 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.

4. Inventories

March 31,
June 30,
(in thousands)20232022
Inventories:
        Raw Material$1,050 $1,010 
        Work-In-Process144 138 
        Finished Goods821 806 
Total inventories$2,015 $1,954 
Allowance for obsolete inventory(350)(350)
Inventories, net$1,665 $1,604 

5. Related Party Transactions and Preferred Stock

11

    On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as March 31, 2023 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2023, and June 30, 2022 the cumulative dividends payable are $264,466 ($0.1322 per share) and $225,731 ($0.1129 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.

6. Line of Credit

    On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The interest rate was 8.24% as of March 31, 2023. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr.

As of June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $4,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively. The line of credit interest expense was approximately $11,000 and $8,000 for the nine months ended March 31, 2023 and 2022, respectively. TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 ("the Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions. $168,313 was reported as long term note payable as of March 31, 2023.
Year ending June 30,
TD Note Payment
2023 (remainder of FY 2023)
$8,023 
12

2024
34,057 
2025
37,434 
2026
41,145 
202745,224 
Thereafter
35,692 
Total
$201,575 

7. Long-term debt

Paycheck Protection Program ("PPP") loan

    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated statement of operations for the nine-month period ended March 31, 2022.

Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of March 31, 2023 are as follows:
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)$753 
20243,084 
20253,202 
20263,324 
20273,451 
Thereafter136,145 
Total$149,959 

8. Concentration of Credit Risk

Credit Risk

Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    No customer accounted for more than 10% of net revenue during the three and nine-month periods ended March 31, 2023. No customer accounted for more than 10% during the three-month period ended March 31, 2022. One customer accounted for 12% of net sales during the nine-month period ended March 31, 2022.

13

    As of March 31, 2023 the Company had one customer that represented 11% of the total accounts receivable balance. As of June 30, 2022 the Company had one customer that represents 13% of the total accounts receivable balance.

Major Supplier

    The Company's two largest suppliers accounted for 44% and 11% of the total purchase for the three-month period ended March 31, 2023. The Company's two largest suppliers accounted for 44% and 10% of the total purchase for the nine-month period ended March 31, 2023. The Company's two largest supplier accounted for 37% and 16% of total purchases for the three-month period ended March 31, 2022. The Company's two largest suppliers accounted for 39% and 13% of total purchases for the nine-month period ended March 31, 2022.

    As of March 31, 2023, the Company had one supplier that represented 47% of the total accounts payable balance. As of June 30, 2022, the Company had one supplier that represent approximately 36% of the total accounts payable balance.
Disaggregated Revenue

    Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended March 31,For the Nine Months Ended March 31,
2023202220232022
Domestic$1,903 55 %$1,266 52 %$5,258 58 %$4,251 55 %
Foreign1,531 45 %1,150 48 %3,787 42 %3,541 45 %
Total$3,434 100 %$2,416 100 %$9,045 100 %$7,792 100 %

9. Leases

    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2023 and 2022 as follows:

Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Operating lease costs:
Fixed$85,324 $84,245 $256,084 $252,735 
Total:$85,324 $84,245 $256,084 $252,735 

    Supplemental cash flow information was as follows:
Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$86,350 $84,187 $256,883 $250,365 
Total$86,350 $84,187 $256,883 $250,365 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2023:
14

Operating
2023 (reminder of FY 2023)$86,358 
2024350,142 
2025211,215 
20262,728 
Total lease payments650,443 
Less interest 33,316 
Present value of lease liabilities$617,127 

    Average lease terms and discount rates were as follows:
March 31,June 30,
20232022
Weighted-average remaining lease terms (years)
Operating leases
1.932.61
Weighted-average discount rate
Operating leases
5.65 %5.65 %

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

    Certain statements contained in, or incorporated by reference in, this report are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. Such statements can be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “should,” “will,” and similar words or expressions. The Company's forward-looking statements include certain information relating to general business strategy, growth strategies, financial results, liquidity, the Company's ability to continue as a going concern, discontinued operations, research and development, product development, the introduction of new products, the potential markets and uses for the Company's products, the Company's ability to increase its sales campaign effectively, the Company's regulatory filings with the FDA, acquisitions, dispositions, the development of joint venture opportunities, intellectual property and patent protection and infringement, the loss of revenue due to the expiration or termination of certain agreements, the effect of competition on the structure of the markets in which the Company competes, increased legal, accounting and Sarbanes-Oxley compliance costs, information security, cybersecurity and data privacy risks, defending the Company in litigation matters and the Company's cost saving initiatives. The reader must carefully consider forward-looking statements and understand that such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by assumptions that fail to materialize as anticipated, including risks related to the COVID-19 pandemic, inflation, the ability to continue as a going concern including the ability to raise capital, manage operations and pursue business partnerships and cost-cutting measures, and the other risks described in the Company's Form 10-K for the fiscal year ended June 30, 2022. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. It is not possible to foresee or identify all factors affecting the Company's forward-looking statements, and the reader therefore should not consider the list of such factors contained in its periodic report on Form 10-K for the year ended June 30, 2022 and this Form 10-Q quarterly report to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.

Executive Overview—nine-month periods ended March 31, 2023 and 2022
The following highlights are discussed in further detail within this Form 10-Q. The reader is encouraged to read this Form 10-Q in its entirety to gain a more complete understanding of factors impacting Company performance and financial condition.

15

•Consolidated net revenue increased approximately $1,253,000 or 16.1%, to $9,045,000 during the nine months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in net revenue is attributed to an increase in Sonomed's ultrasound products of $1,283,000, an increase in sales of AXIS products of $24,000 and an increase in Trek revenue of $13,000 offset by a decrease in service plans revenue of $68,000.

•Consolidated cost of goods sold totaled approximately $5,021,000, or 55.5%, of total revenue for the nine months ended March 31, 2023, as compared to $4,681,000, or 60.1%, of total revenue of the same period of last fiscal year. The decrease of 4.6% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences.

•Consolidated marketing, general and administrative expenses increased $253,000, or 8.9%, to $3,108,000 for the nine months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in marketing, general and administrate expenses is mainly due to increased network expense, increased consulting expense related to a regulatory filing related to AXIS products, and increased sales compensation offset by recovery of bad debt expense of $113,000.

•Consolidated research and development expenses decreased $140,000, or 17.9%, to $641,000 for the nine months ended March 31, 2023, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to decreased consulting expense during the nine months ended March 31, 2023.
Company Overview

    The following discussion should be read in conjunction with the interim unaudited condensed consolidated financial statements and the notes thereto, which are set forth in Item 1 of this report.

    The Company operates in the healthcare market specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the FDA. The FDA requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The Company's Internet address is www.escalonmed.com. Under the trade name of Sonomed-Escalon the Company develops, manufactures and markets ultrasound systems used for diagnosis or biometric applications in ophthalmology, develops, manufactures and distributes ophthalmic surgical products under the Trek Medical Products name, and manufactures and markets image management systems.
Critical Accounting Policies and Estimates
The preparation of unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact amounts reported therein. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

For a description of the accounting policies that, in management’s opinion, involve the most significant application of judgment or involve complex estimation and which could, if different judgment or estimates were made, materially affect our reported financial position, results of operations, or cash flows, see the notes to consolidated financial statements included in the Form 10-K for the year ended June 30, 2022.

During the nine months ended March 31, 2023, there were no significant changes in our accounting policies and estimates to our unaudited condensed consolidated financial statements.
16

Results of Operations
Three Months and Nine Months Ended March 31, 2023, and 2022
The following table shows consolidated net revenue, as well as identifying trends in revenues for the three months and nine months ended March 31, 2023, and 2022. Table amounts are in thousands:
 For the Three Months Ended March 31,For the Nine Months Ended March 31,
 20232022% Change20232022% Change
Net Revenue:
Products$3,285 $2,260 45.4 %$8,583 $7,261 18.2 %
Service plans149 156 (4.5)%462 531 (13.0)%
Total$3,434 $2,416 42.1 %$9,045 $7,792 16.1 %
    
Consolidated net revenue increased approximately $1,018,000 or 42.1%, to $3,434,000 during the three months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in net revenue is attributed to an increase in Sonomed's ultrasound products of $922,000, an increase in sales of AXIS products of $50,000 and an increase in Trek revenue of $53,000 offset by a decrease in service plans revenue of $7,000.

Consolidated net revenue increased approximately $1,253,000 or 16.1%, to $9,045,000 during the nine months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in net revenue is attributed to an increase in Sonomed's ultrasound products of $1,283,000, an increase in sales of AXIS products of $24,000 and an increase in Trek revenue of $13,000 offset by a decrease in service plans revenue of $68,000.
The following table presents the domestic and foreign sales for the three months and nine months ended March 31, 2023, and 2022. The table amounts are in thousands:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2023202220232022
Domestic$1,903 55.4 %$1,266 52.4 %$5,258 58.1 %$4,251 54.6 %
Foreign1,531 44.6 %1,150 47.6 %3,787 41.9 %3,541 45.4 %
Total$3,434 100.0 %$2,416 100.0 %$9,045 100.0 %$7,792 100.0 %

The following table presents consolidated cost of goods sold and as a percentage of revenues for the three months and nine months ended March 31, 2023, and 2022. Table amounts are in thousands:

 
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2023%2022%2022%2022%
Cost of Goods Sold:
$1,721 50.1 %$1,478 61.2 %5,021 55.5 %4,681 60.1 %
Total$1,721 50.1 %$1,478 61.2 %5,021 55.5 %4,681 60.1 %


Consolidated cost of goods sold totaled approximately $1,721,000, or 50.1%, of total revenue for the three months ended March 31, 2023, as compared to $1,478,000, or 61.2%, of total revenue of the same period of last fiscal year. The decrease of 11.1% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences.

Consolidated cost of goods sold totaled approximately $5,021,000, or 55.5%, of total revenue for the nine months ended March 31, 2023, as compared to $4,681,000, or 60.1%, of total revenue of the same period of last fiscal year. The decrease of 4.6% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences.

    The following table presents consolidated marketing, general and administrative expenses for three months and nine months ended March 31, 2023 and 2022. Table amounts are in thousands:
17

 
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20232022% Change 20232022% Change 
Marketing, General and Administrative:
$938 $1,001 (6.3)%$3,108 $2,855 8.9 %
Total$938 $1,001 (6.3)%$3,108 $2,855 8.9 %

Consolidated marketing, general and administrative expenses decreased $63,000, or 6.3%, to $938,000 for the three months ended March 31, 2023, as compared to the same period of last fiscal year. The decrease in marketing, general and administrate expenses is mainly due to recovery of bad debt expense of $113,000 and decreased consulting expense offset by increased network expense and sales compensation.

Consolidated marketing, general and administrative expenses increased $253,000, or 8.9%, to $3,108,000 for the nine months ended March 31, 2023, as compared to the same period of last fiscal year. The increase in marketing, general and administrate expenses is mainly due to increased network expense, increased consulting expense related to a regulatory filing related to AXIS products, and increased sales compensation offset by recovery of bad debt expense of $113,00.

The following table presents consolidated research and development expenses for the three months and nine months ended March 31, 2023, and 2022.
Table amounts are in thousands:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20232022% Change  20232022% Change
Research and Development:
$186 $229 (18.8)%641 $781 (17.9)%
Total$186 $229 (18.8)%$641 $781 (17.9)%

Consolidated research and development expenses decreased $43,000, or 18.8%, to $186,000 for the three months ended March 31, 2023, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to decreased consulting expense during the three months ended March 31, 2023.
Consolidated research and development expenses decreased $140,000, or 17.9%, to $641,000 for the nine months ended March 31, 2023, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to decreased consulting expense during the nine months ended March 31, 2023.
Other income
  
On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The promissory note has a fixed payment schedule. The PPP loan is unsecured. The Company submitted the loan forgiveness application on August 2, 2021. The full amount of the PPP loan and accrued interest of $6,305 were forgiven on August 13, 2021, and reported as other income during the nine-month period ended March 31, 2022.


Russia-Ukraine War

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which it does business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations.
18


Liquidity and Capital Resources

Our total cash on hand as of March 31, 2023 was approximately $544,000 of cash on hand and restricted cash of approximately $256,000 compared to approximately $594,000 of cash on hand and restricted cash of $256,000 as of June 30, 2022.

Because the Company's operations have not historically generated sufficient revenues to enable profitability, we will continue to monitor costs and expenses closely and may need to raise additional capital or take other actions in order to fund operations.

The Company expects to continue to fund operations from cash on hand and through capital raising sources if possible and available, which may be dilutive to existing stockholders, through revenues from the licensing of the Company's products, or through strategic alliances. Additionally, we may seek to sell additional equity or debt securities through one or more discrete transactions, or enter into a strategic alliance arrangement, but can provide no assurances that any such financing or strategic alliance arrangement will be available on acceptable terms, or at all. Moreover, the incurrence of indebtedness in connection with a debt financing would result in increased fixed obligations and could contain covenants that would restrict our operations.

As of March 31, 2023 we had an accumulated deficit of approximately $68.6 million, historically incurred recurring losses from operations and negative cash flows from operating activities. These factors raise substantial doubt regarding our ability to continue as a going concern, and our ability to generate cash to meet our cash requirements for the following twelve months as of the date of this form 10-Q.
    
The following table presents overall liquidity and capital resources as of March 31, 2023 and June 30, 2022. Table amounts are in thousands:
 
March 31,June 30,
 20232022
Current Ratio:
Current assets$4,371$4,186
Less: Current liabilities2,7753,002
Working capital$1,596$1,184
Current ratio1.58 to 11.39 to 1
Debt to Total Capital Ratio:
Line of credit, note payable, lease liabilities, and EIDL loan$973$1,205
Total debt 9731,205
Total equity 1,7361,478
Total capital $2,709$2,683
Total debt to total capital 35.9%44.9%
19

Working Capital Position
Working capital increased approximately $412,000 as of March 31, 2023, and the current ratio increased to 1.58 to 1 from 1.39 to 1 when compared to June 30, 2022. The increase in working capital is due to a decrease in current liabilities of $227,000 when a loan of $ 201,575 was converted to a sixty-month note payable on March 29, 2023 and an increase in current assets of $185,000 due to operating income.
Debt to total capital ratio was 35.9% and 44.9% as of March 31, 2023 and June 30, 2022, respectively. The decrease of debt to total capital ratio is mainly due to operating income.
Cash Flow Used in Operating Activities
During the nine months ended March 31, 2023 the Company used approximately $30,000 of cash in operating activities as compared to cash of approximately $597,000 used in operating activities during the nine months ended March 31, 2022.
    For the nine months ended March 31, 2023, its cash used in operations is due to operating income of $258,000, an increase in accounts payable of $35,000, and a decrease in other current and non-current assets of $28,000, offset by an increase in accounts receivable of approximately $108,000, an increase of inventory of $61,000, a repayment of employer tax deferral of $43,000, and a decrease of other deferred revenue of $37,000 and a decrease in accrued expense of $33,000. The remaining offsetting items for cash provided by operations is comprised of less significant items.
    For the nine months ended March 31, 2022, its cash used in operations is mainly as a result of net loss, including the non-cash adjustment for PPP loan forgiveness, along with the increase in inventories of $128,000, an increase in accounts receivable of approximately $63,000, a decrease in deferred revenue of $61,000, a repayment of employer tax deferral of $41,000, and decrease in operating liabilities of $217,000 offset by an increase in accrued expense of $184,000. The remaining offsetting items for cash provided by operations is comprised of less significant items.
Cash Flows used in Investing Activities
Cash flows used in investing activities for the nine-month period ended March 31, 2023 was due to the addition to the patent of $7,000 and addition to the fixed assets of $7,000. There were no cash flows used in investing activities for the nine-month period ended March 31, 2022.
Cash Flows Used in Financing Activities
For the nine months ended March 31, 2023 the cash used in financing activities was due to an auto loan payment of $3,000 and repayment of EIDL loan of $3,000. For the nine months ended March 31, 2022 the cash used in financing activities was due to auto loan payment of employer $3,000 and repayment of EIDL loan of $2,000.
Debt Financing

    On June 29, 2018 the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.000% per annum. Interest on the unpaid principal balance of the note will be calculated using a rate of 0.740 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.740% per annum based on a year of 360 days. The interest rate was 8.24% as of March 31, 2023. The Company was required to put $250,000 in the TD bank savings account as collateral.
    
    As of June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $4,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively. The line of credit interest expense was approximately $11,000 and $8,000 for the nine months ended March 31, 2023 and 2022, respectively. TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 ("the Conversion Date"). Sixty scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions. $168,313 was reported as long term note payable as of March 31, 2023.



COVID-19 Relief Loans and Liabilities

Payroll Protection Program ("PPP")

20

    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021, and reported as other income during the nine-month period ended March 31, 2022.

Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received $150,000 EIDL loan. The annual interest rate is 3.75%, the payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4. Controls and Procedures

(A)    Evaluation of Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Principal Financial and Accounting Officer, have established disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the officers who certify the Company's financial reports and to other members of senior management and the Board of Directors.

Based on their evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2023, the Chief Executive Officer and Principal Financial and Accounting Officer of the Company have concluded that such disclosure controls and procedures are not effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its Chief Executive Officer and Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosure. We identified a material weakness in internal control related to the proper design and implementation of controls over our estimates relating to the valuation of inventory and allowance for doubtful accounts, specifically over the precision of management’s review during the year end June 30, 2022.


(B)    Internal Control over Financial Reporting

There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act), during the third quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II. OTHER INFORMATION

Item 6.    Exhibits
21



Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Escalon Medical Corp.
(Registrant)
Date: May 15, 2023By:/s/ Richard J. DePiano, Jr.
Richard J. DePiano, Jr.
Chief Executive Officer
Date: May 15, 2023By:/s/ Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer

22
Escalon Medical (QB) (USOTC:ESMC)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Escalon Medical (QB).
Escalon Medical (QB) (USOTC:ESMC)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Escalon Medical (QB).